MARKET PULSE-Zale, Garmin, Eli Lilly, Potbelly, Herbalife
(For more market insights, including options activity, click on ; for the Day Ahead newsletter link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index futures fell on Wednesday on investor caution ahead of the release of housing data and minutes from the Federal Reserve's latest meeting of policymakers. Dow Jones industrial average futures were down 0.23 percent at 16,070, S&P 500 futures were down 0.22 percent at 1,833.4 and Nasdaq 100 futures were down 0.10 percent at 3,671.5.
** CHELSEA THERAPEUTICS INTERNATIONAL LTD, Tuesday close $4.95, +32.53 pct premarket
The company's drug Northera, which treats a rare form of low blood pressure associated with neurological disorders such as Parkinson's disease, has won U.S. approval, the Food and Drug Administration said on Tuesday.
** SIGNET JEWELERS LTD, Tuesday close $79.27, +12.27 pct premarket
** ZALE CORP, Tuesday close $14.91, +40.17 pct premarket
Kay Jewelers parent Signet Jewelers agreed to buy smaller rival Zale Corp for about $690 million, cementing its position as the largest North American jewelry chain.
The offer of $21 per share represents a premium of about 41 percent to Zale's close on the New York Stock Exchange on Tuesday. The stock traded as low as $3.76 in April. Continued...